Cyteir Therapeutics Inc

-0.03 (-2.21%)
4:00:14 PM EDT: $1.33 0.00 (0.00%)
Earnings Announcements

Cyteir Therapeutics Inc Reports Q3 Loss Per Share Of $0.31

Published: 11/07/2022 21:41 GMT
Cyteir Therapeutics Inc (CYT) - Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights.
Q3 Loss per Share $0.31.
Initial Data From Cyt-0851 Monotherapy Solid Tumor Phase 2 Cohorts Are Now Expected in Q1 of 2023.
Initial Data From Phase 1 Combination Solid Tumor Cohorts Are Expected in First Half of 2023.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.34

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.36

More details on our Analysts Page.